-5%
LinezolidÂ
- Hospital-acquired pneumonia (nosocomial)
- Community-acquired pneumonia
- Complicated skin and soft tissue infections (including diabetic foot ulcers without bone involvement)
- Uncomplicated skin and soft tissue infections
- Infections caused by vancomycin-resistant Enterococcus faecium
Note: Linzolid is not effective against Gram-negative infections. Safety for use beyond 28 days has not been studied in clinical trials.
Linezolid is a synthetic oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 23S portion of the 50S ribosomal subunit, preventing formation of the 70S initiation complex.
Bacteriostatic against staphylococci and enterococci
Bactericidal against most streptococci
